Cargando…

Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition

Improved prognosis for triple-negative breast cancer (TNBC) has currently plateaued and the development of novel therapeutic strategies is required. Therefore, we aimed to explore the anti-tumor effect of eribulin and paclitaxel combination therapy for TNBC. The effect of eribulin and paclitaxel in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oba, Takaaki, Ito, Ken-Ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955406/ https://www.ncbi.nlm.nih.gov/pubmed/29796167 http://dx.doi.org/10.18632/oncotarget.25184

Ejemplares similares

ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines
por: Oba, Takaaki, et al.
Publicado: (2016)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
por: Pederson, Petra J., et al.
Publicado: (2021)

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2019)

Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line
por: Yahiro, Kenichiro, et al.
Publicado: (2018)

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma
por: Sampson, Valerie B., et al.
Publicado: (2016)

Curcumol enhances the anti-tumor effects of metformin via suppressing epithelial-mesenchymal transition in triple-negative breast cancer
por: Wang, Gangyue, et al.
Publicado: (2020)

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
por: Ho, Gwo Yaw, et al.
Publicado: (2022)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
por: Yoshida, T, et al.
Publicado: (2014)

Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition
por: Kitahara, Hiroko, et al.
Publicado: (2016)

Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting β-Tubulin in Triple-Negative Breast Cancer
por: Fu, Yun, et al.
Publicado: (2020)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

A novel anti-lung cancer agent inhibits proliferation and epithelial–mesenchymal transition
por: Zhao, Wen, et al.
Publicado: (2022)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer
por: Bhatt, Akshita B., et al.
Publicado: (2019)

Intratumoral bidirectional transitions between epithelial and mesenchymal cells in triple‐negative breast cancer
por: Yamamoto, Mizuki, et al.
Publicado: (2017)

Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment
por: Font-Clos, Francesc, et al.
Publicado: (2022)

Orally Active and Selective Tubulin Inhibitors as Anti-Trypanosome Agents
por: Nanavaty, Vishal, et al.
Publicado: (2016)

Resistance to anti-tubulin agents: From vinca alkaloids to epothilones
por: Krause, Werner
Publicado: (2019)

NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling
por: Zhang, Jianchao, et al.
Publicado: (2016)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine
por: Yang, Fan, et al.
Publicado: (2023)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo
por: Piperigkou, Zoi, et al.
Publicado: (2022)

Intercellular Communication Reveals Therapeutic Potential of Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer
por: Liu, Yang, et al.
Publicado: (2022)

Anti-Cancer Potential of Phytochemicals: The Regulation of the Epithelial-Mesenchymal Transition
por: Liu, Shuangyu, et al.
Publicado: (2023)

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
por: Wen, Wei, et al.
Publicado: (2019)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Gene Expression Profiling Reveals Epithelial Mesenchymal Transition (EMT) Genes Can Selectively Differentiate Eribulin Sensitive Breast Cancer Cells
por: Dezső, Zoltán, et al.
Publicado: (2014)

Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer
por: Cantini, Laura, et al.
Publicado: (2019)

Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition
por: Garcia, Elizabeth, et al.
Publicado: (2021)

Inhibiting parasite proliferation using a rationally designed anti‐tubulin agent
por: Gaillard, Natacha, et al.
Publicado: (2021)

In silico analysis of noscapine compounds as anti-tumor agents targeting the tubulin receptor
por: Nulamuga, Benson, et al.
Publicado: (2022)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
por: Takahashi-Ruiz, Leila, et al.
Publicado: (2022)

Eupalinilide B as a novel anti-cancer agent that inhibits proliferation and epithelial–mesenchymal transition in laryngeal cancer cells
por: Jiang, Linlin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k8ser4ue99evav7lahfd8k4uog